Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - BG Medicine, Inc.Financial_Report.xls
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R2.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R4.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R8.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R1.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R6.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R7.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R9.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R19.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R10.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R16.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R12.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R21.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R20.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R11.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R17.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R22.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R14.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R13.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R18.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R15.htm
EX-32 - EX-32 - BG Medicine, Inc.d398643dex32.htm
EX-10.1 - EX-10.1 - BG Medicine, Inc.d398643dex101.htm
EX-31.2 - EX-31.2 - BG Medicine, Inc.d398643dex312.htm
EX-10.2 - EX-10.2 - BG Medicine, Inc.d398643dex102.htm
10-Q - FORM 10-Q - BG Medicine, Inc.d398643d10q.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R3.htm
EX-31.1 - EX-31.1 - BG Medicine, Inc.d398643dex311.htm
v2.4.0.6
Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)
In Thousands, unless otherwise specified
9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Cash flows from operating activities    
Net loss $ (20,870) $ (12,848)
Adjustments to reconcile net loss to net cash used in operating activities    
Depreciation and amortization 210 330
Stock-based compensation 1,881 1,291
Non-cash interest expense and changes in fair value of warrant liability 139 124
Changes in operating assets and liabilities    
Restricted cash 92 (631)
Accounts receivable (32) 698
Inventory (240) (330)
Prepaid expenses and other current assets (96) (319)
Accounts payable and accrued expenses 2,583 568
Deferred revenue and customer deposits (188) (79)
Net cash flows used in operating activities (16,521) (11,196)
Cash flows from investing activities    
Purchases of property and equipment and intangibles (85) (65)
Purchases of investments   (16,048)
Proceeds from sales and maturities of investments   1,800
Net cash flows used in investing activities (85) (14,313)
Cash flows from financing activities    
Proceeds from initial public offering   37,433
Proceeds from issuance of term loan 10,000  
Payments on term loan   (100)
Costs related to initial public offering   (1,295)
Costs related to term loan issuance (256)  
Proceeds from ESPP purchase 30  
Proceeds from the exercise of stock options 537 147
Net cash flows provided by financing activities 10,311 36,185
Net (decrease) increase in cash and cash equivalents (6,295) 10,676
Cash and cash equivalents, beginning of period 23,874 2,425
Cash and cash equivalents, end of period 17,579 13,101
Supplemental disclosure of cash flow information    
Cash paid for interest 532 2
Supplemental disclosure of non-cash activities    
Settlement of 2011 accrued bonus with stock issuance 22  
Issuance of common stock warrants 240  
Conversion of preferred stock   73,919
Conversion of bridge notes and accrued interest   6,361
Conversion of warrant liability   $ 272